Novartis announced successful results from two phase 3 trials of ianalumab, targeting BAFF-R in patients with Sjögren's syndrome. Both Neptunus 1 and 2 studies met their primary endpoints, showing statistically significant reductions in disease activity at 52 weeks compared with placebo. The drug demonstrated a favorable safety profile and represents the first globally validated targeted therapy for this autoimmune condition. Novartis plans to engage health authorities to pursue regulatory approvals, positioning ianalumab as a potential first-in-class treatment amid limited existing options. This win comes after Novartis discontinued its anti-CD40 antibody program, making ianalumab the company's lead candidate in Sjögren's syndrome.